Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian Securities Exchange. Imagion issued 60 million new shares as part of the IPO at A$0.20 per share, valuing the company at A$43 million upon listing.
The company’s shares trade under the symbol IBX on the Australian Securities Exchange. Download the official announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)